Source: Times of India 6th May’08, (Tuesday)
Mumbai: Diabetes, Cardiac and gastrointestinal hold sway in India, where chronic therapies comprise more than 40% of the entire market. Like developed markets, India is gradually shifting to lifestyle disorders. And drug companies are profiting form diabetes and cardiovascular cases.
The over searching trend of lifestyle diseases is dictating the fortunes of various therapeutic categories. Prescriptions for diabetes have grown over 15% compounded since 2000 in urban India. With India poised to have the largest number diabetics in future, the antidiabetic therapeutic area has had the highest growth rate of 26.1%, followed by cardiology at 21.3% and gynaecology at 18.3%, according to ORG-IMS data. The antidiabetic segment has grown from 19.5 %( MAT December 2006) to 26.1%
(MAT December 2007). The gynaecology segment too recorded growth from 15.9% to 18.3% m during the same period.
Not only are drug majors benefiting from the growing cases of diabetes and gastrointestinal illness, several therapeutic segments have witnessed a high number of new product launches in recent years.” It is not just new drugs coming into the market .MNCs like Novo Nordisk and Elli Lilly have launched insulin pens which are patient compliant,” said Ranjit Kapadia of Prabhudas Lilladher, a financial services firm.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment